^
    1m
    TITAN: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. (clinicaltrials.gov)
    P1, N=72, Recruiting, AstraZeneca | N=54 --> 72
    Enrollment change
    1m
    Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers. (PubMed, J Immunother Cancer)
    The combination of rhIL-15 with nivolumab and ipilimumab was safe and induced changes in immune cell populations in some patients. However, preliminary signs of efficacy were limited. Pharmacodynamic findings may support further clinical development of this combination with alternative dosing regimens or combinations of rhIL-15 with other therapeutic modalities.
    P1 data • PK/PD data • Journal
    |
    PD-1 (Programmed cell death 1) • IL15 (Interleukin 15)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • rhIL-15
    2ms
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations (clinicaltrials.gov)
    P1, N=24, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting | Trial completion date: Feb 2026 --> Jan 2028 | Trial primary completion date: Feb 2026 --> Jan 2028
    Enrollment open • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    3ms
    A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies (clinicaltrials.gov)
    P1, N=27, Recruiting, Abalos Therapeutics GmbH
    New P1 trial • Checkpoint inhibition
    |
    Keytruda (pembrolizumab)
    3ms
    Phase 2 trial (NCI-COTC030) of adjuvant inhaled recombinant human IL-15 combined with amputation and adjuvant chemotherapy in dogs with appendicular osteosarcoma. (PubMed, Front Immunol)
    Correlative assays suggest significant immunological effects of amputation and chemotherapy on immune responses. These data have important implications on novel immunotherapy strategies involving multimodality approaches including surgery and chemotherapy.
    P2 data • Journal • IO biomarker
    |
    IL6 (Interleukin 6) • IL15 (Interleukin 15)
    |
    rhIL-15
    3ms
    TITAN: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies. (clinicaltrials.gov)
    P1, N=54, Recruiting, AstraZeneca | Trial primary completion date: Feb 2027 --> Jun 2027
    Trial primary completion date
    3ms
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations (clinicaltrials.gov)
    P1, N=24, Suspended, Fred Hutchinson Cancer Center | Active, not recruiting --> Suspended
    Trial suspension • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    5ms
    Efficacy of VTP-300 in Chronic Hepatitis B Infection (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Barinthus Biotherapeutics | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial primary completion date
    |
    Opdivo (nivolumab)
    5ms
    KEYNOTE-E29: A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=552, Active, not recruiting, Asher Biotherapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • etakafusp alfa (AB248)
    5ms
    ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=375, Recruiting, Immatics US, Inc. | Phase classification: P1 --> P1/2 | Trial completion date: Dec 2028 --> Jun 2032
    Phase classification • Trial completion date
    |
    Opdivo (nivolumab) • IMA203CD8 • anzutresgene autoleucel (IMA203)
    6ms
    Asher-BioAB821: AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AB821
    8ms
    A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies. (PubMed, Blood Neoplasia)
    Recombinant human interleukin-15 (rhIL-15) is an immunotherapeutic agent that enhances natural killer (NK) cells to augment the antibody-dependent cellular cytotoxicity (ADCC) of monoclonal antibodies. Future development of combinations of immunotherapy that target the microenvironment in relapsed or refractory T-cell lymphomas remains rational. This trial was registered at www.ClinicalTrials.gov as #NCT04185220.
    Clinical • P1 data • Journal
    |
    IL15 (Interleukin 15)
    |
    Poteligeo (mogamulizumab-kpkc) • rhIL-15